Irs-19 spray nasal 20ml

Description

Composition
Active substance:
Acinetobacter calcoaceticus lysate 3.33 mL, Enterococcus faecalis lysate 0.73 mL, Enterococcus faecium lysate 0.83 mL, Haemophilus influenzae [type B] Lysate 3.33 ml, Klebsiella pneumoniae lysate 6.66 mL, Moxarella catarrhalis lysate 2.22 mL, Neisseria perflava lysate 2.22 mL, Neisseria subflava lysate 2.22 ml, Staphylococcus aureus lysate 9.99 ml, Streptococcus dysgalactiae [group C] lysate 1.66 ml, Streptococcus pneumoniae [type I] lysate 1.11 ml, Streptococcus pneumoniae [type II] lysate 1.11 ml, Streptococcus pneumoniae [type III] lysate 1.11 ml, Streptococcus pneumoniae [type V] lysate 1.11 ml, Streptococcus pneumoniae [type VIII] lysate 1.11 ml, Streptococcus pneumoniae [type XII] lysate 1.11 ml, Streptococcus pyogenes [group A] lysate 1.66 ml, Streptococcus lysate [group G] 1.66 ml – 100 ml.
Excipients:
Glitsin4,25 g Sodium Merthiolate not bolee1,2 mg Flavor based nerol mg ** 12.50 ** Composition based flavoring nerol: linalool, alpha-terpineol, geraniol, methyl anthranilate, limonene, geranyl, linalyl acetate, diethylene glycol monoethyl ether diethylene glycol, phenylethyl alcohol.
Description:
Transparent colorless or yellowish white liquid with a faint characteristic odor.
When IRS®19 formed a fine aerosol spray which coats the nasal mucosa, which leads to the rapid development of local immune response. Specific protection is due to a locally generated antibodies secretory immunoglobulin class type A (IgA), manifested preventing fixing and reproduction of pathogens to mucosal infection. Non-specific immune defenses is to increase the phagocytic activity of macrophages and increase the content of lysozyme.
Product form:
Nasal spray.
20 ml aerosol balloon of a colorless transparent low alkaline glass, coated with a protective layer of plastic, pressurized nitrogen, with a continuous valve, complete with high packing density of white polyethylene. In balloon paste adhesive label or marking is applied to the protective plastic layer by screen printing or dry offset. 1 cylinder complete with nozzle and instructions for use placed in a cardboard box.
Contraindications
Increased sensitivity to the drug or its components in history.
IRS®19 should not be administered to patients with autoimmune diseases.
Indications
Prevention of chronic respiratory diseases and bronchial tubes.
Treatment of acute and chronic respiratory diseases and bronchial tubes, such as rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis, and others.
Restoring local immunity after an influenza and other viral infections.
Preparations for the planned surgery on the upper respiratory tract and in the postoperative period.
Interaction with other drugs
Cases of adverse interactions with other drugs known. In the case of the onset of clinical symptoms of the bacterial infection is possible antibiotics with continued application IRS®19.
Overdose
Cases of overdose are unknown.
pharmachologic effect
Pharmacological group:
Immunostimulatory preparation based on bacterial lysates.
ATX code: R07AX.
Pregnancy and breast-feeding
There are not enough data about the potential teratogenic or toxic effects on the fetus during pregnancy, so the use of the drug during pregnancy is not recommended.
Conditions of supply of pharmacies
Without recipe.
side effects
During reception IRS®19 may experience side effects such as the following related and unrelated to the action of the drug.
Cutaneous reactions: In rare cases of hypersensitivity reactions (urticaria, angioneurotic edema) and skin and eritemopodobnye ekzemopodobnye reaction.
On the part of upper respiratory tract and the respiratory system: in rare cases – asthma and cough.
In rare cases, early treatment can be observed: fever (
Described isolated cases of the appearance of thrombocytopenic purpura, and erythema nodosum.
When the above symptoms it is recommended to consult a doctor.
special instructions
Very important!
The device functions correctly only when the following conditions:
Attach the nozzle on the bottle, how to center it and gently, without effort, click on it. Now the device is ready for use.
When spraying PREPARATION TO HOLD bottle upright and not throw back his head.
If you tilt the bottle while spraying, a propellant will flow for a few seconds and the device will become worthless.
It is not recommended to remove the nozzle at regular use of the drug.
If the drug is left on for a long time without use, a drop of liquid can evaporate and the resulting crystals clog the nozzle outlet opening. This phenomenon occurs most often when the nozzle is removed and placed in the upper end of the package down next to a bottle without first washing and dry it. If the nozzle is clogged, click on it a few times, so that the liquid could pass under the influence of excess pressure. If this does not help, lower the nozzle for a few minutes in warm water.
Early treatment in rare cases, may rise in temperature (to 39 ° C). In this case, treatment should be discontinued. However, such a condition should be distinguished from the increase in body temperature, accompanied by malaise, which may be associated with the development of diseases of upper respiratory tract. In the presence of clinical signs of systemic bacterial infection should consider whether systemic antibiotics.
When prescribing based on bacterial lysates for the purpose of immunostimulation patients with bronchial asthma may cause asthma attacks. In this case, it is recommended to stop treatment or take drugs of this class in the future.
Application IRS®19 no effect on psychomotor functions related to driving or control machines and mechanisms.
Storage conditions
In the upright position at a temperature not higher than 25 ° C.
Do not freeze.
Precautions for the use of
Spray Bottle:
Protect from heat above 50 ° C and from direct sunlight.
Do not pierce the vial.
Do not burn a bottle, even if it is empty.
Dosing and Administration
The drug used intranasally by aerosol administration 1st dose (1 dose = 1 short press atomizer).
In order to prevent adults and children from 3 months to 1 st dose of the drug in each nostril 2 times a day for 2 weeks (to start a course of treatment is recommended for 2-3 weeks before the expected rise of morbidity).
For the treatment of acute and chronic diseases of the upper respiratory tract and bronchi: – Children from 3 months to 3 years for a single dose of the drug in each nostril 2 times a day, after a preliminary release of mucous discharge, until the disappearance of symptoms of the infection. – children older than 3 years and adults at a single dose of the drug in each nasal passage from 2 to 5 times a day until the disappearance of symptoms of the infection.
To restore local immunity of children and adults after suffering the flu and other respiratory viral infections of the 1st dose of the drug in each nostril 2 times a day for 2 weeks.
In preparation for the planned surgery and in the postoperative period in adults and children of 1st dose of the drug in each nostril 2 times a day for 2 weeks (to start a course of treatment is recommended for 1 week before the planned surgery).
Early treatment may occur such reactions as sneezing and increased nasal secretion. As a rule, they are of short duration. If these reactions will take a severe course, reduce the frequency of administration of the drug or cancel it.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist